SAN DIEGO--(BUSINESS WIRE)--PURE Bioscience (NASDAQ: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fourth quarter and fiscal year ended July 31, 2010 (“Fiscal 2010”).
SAN DIEGO--(BUSINESS WIRE)--PURE Bioscience (NASDAQ: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fourth quarter and fiscal year ended July 31, 2010 (“Fiscal 2010”).
